Viking Therapeutics Inc (VKTX)

[DMOST]

VKTX: Final Patient Enrolled in P2 Trial of VK2809; Raises Gross Proceeds of $77.6M in Public Offering

Financial Update

On June 12, 2018, Viking Therapeutics, Inc. (VKTX) announced the closing of a public offering of 8.625 million shares at $9.00 per share, which included 1.125 million shares sold based on the underwriter’s full exercise of their option to purchase additional shares. Gross proceeds to the company will be approximately $77.6 million.

The company exited the first quarter of 2018 with approximately $77.5 million in cash and cash equivalents. Following this most recent financing, we estimate the company will exit the second quarter of 2018 with between $140-$150 million, which should be sufficient to fund operations well into 2020...………..

Business Update

Final Patient Enrolled in Phase 2 Trial of VK2809

https://finance.yahoo.com/quote/VKTX/?p=VKTX&guccounter=1

GO VKTX

"PEACE"